Randomized, Double-blind, Placebo-controlled, Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 22 Sep 2025
At a glance
- Drugs I 022 (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Shanghai Pharmaceuticals Holding
Most Recent Events
- 17 Aug 2025 Planned End Date changed from 31 May 2025 to 31 May 2026.
- 17 Aug 2025 Planned primary completion date changed from 31 May 2025 to 31 May 2026.
- 20 Dec 2024 Planned End Date changed from 16 Dec 2024 to 31 May 2025.